SCHEMBL6429206

SCHEMBL6429206

O=P(O)(O)Cc1cccc(F)c1F

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 2/20 0.52
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
PGK1 P00558 5/20 0.44
PGK2 P07205 5/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
CES2 O00748 1/20 0.41
BCHE P06276 1/20 0.41
CES1 P23141 1/20 0.41
RIPK1 Q13546 1/20 0.40
PIN1 Q13526 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9174132 0.90 ACP3 (0.57) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4287643 0.83 ACP3 (0.55) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL578080 0.77 SMN1; SMN2 (0.57) ACP3PGK1PGK2SMN1; SMN2CES2
SCHEMBL29707862 0.75 ACP3 (0.65) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8053801 0.75 ACP3 (0.65) ACP3GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL5795783 0.73 RIPK1 (0.38) RIPK1PIN1
SCHEMBL112270 0.72 CES2 (0.43) CES2BCHECES1RIPK1
SCHEMBL266645 0.72 RIPK1 (0.49) CES2BCHECES1RIPK1
SCHEMBL424618 0.72 CES2 (0.43) CES2BCHECES1RIPK1
SCHEMBL2957481 0.72 CES2 (0.43) CES2BCHECES1RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10985446-B1 Physically reconfigurable structurally embedded vascular antenna and method of making UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2021-04-20 US claimed
US-10944178-B1 Physically reconfigurable structurally embedded vascular antenna GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE 2021-03-09 US claimed
US-10129975-B1 Liquid metal interfaces for flexible and reconfigurable electronics THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2018-11-13 US claimed
US-20250334727-A1 OPTICAL FILTER, OPTICAL DEVICE, AND LIGHT-ABSORBING COMPOSITION NIPPON SHEET GLASS CO LTD (JP) 2025-10-30 US disclosed
US-20250231329-A1 LIGHT-ABSORBING COMPOSITION, LIGHT-ABSORBING FILM, AND OPTICAL FILTER NIPPON SHEET GLASS CO LTD (JP) 2025-07-17 US disclosed
US-12313869-B2 Optical filter, optical device, and light-absorbing composition NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2025-05-27 US disclosed
US-12287501-B2 Light-absorbing composition, light-absorbing film, and optical filter NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2025-04-29 US disclosed
US-12071542-B2 Light-absorbing composition and optical filter NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2024-08-27 US disclosed
US-20240192414-A1 LAMINATE, VISUAL-LINE TRACKING SYSTEM, AND HEAD-MOUNTED DISPLAY FUJIFILM CORPORATION (JP) 2024-06-13 US disclosed
US-20230400615-A1 OPTICAL FILTER, OPTICAL DEVICE, AND LIGHT-ABSORBING COMPOSITION NIPPON SHEET GLASS COMPANY, LIMITED (JP) 2023-12-14 US disclosed
US-20230322793-A1 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza NOVARTIS AG (CH) 2023-10-12 US disclosed
US-10129975-B1 Liquid metal interfaces for flexible and reconfigurable electronics THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2018-11-13 US disclosed
US-10129975-B1 Liquid metal interfaces for flexible and reconfigurable electronics THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2018-11-13 US disclosed
US-9939727-B2 Method for manufacturing patterned object, patterned object, and light irradiation apparatus USHIO DENKI KABUSHIKI KAISHA (JP) 2018-04-10 US disclosed
US-20170052447-A1 METHOD FOR MANUFACTURING PATTERNED OBJECT, PATTERNED OBJECT, AND LIGHT IRRADIATION APPARATUS USHIO DENKI KABUSHIKI KAISHA (JP) 2017-02-23 US disclosed
US-20050014732-A1 Combination of an aldosterone receptor antagonist and an anti-diabetic agent PHARMACIA CORPORATION (US) 2005-01-20 US disclosed
US-6572986-B2 Subjecting the phosphor, the organic phosphorus compound, and a polyurethane binder to dispersing processing in order to prepare a coating mixture, applying the coating on a substrate to form phoshor layer FUJI PHOTO FILM CO., LTD. (JP) 2003-06-03 US disclosed
US-20010053461-A1 Radiation image storage panel and process for producing the same FUJIFILM CORPORATION (JP) 2001-12-20 US disclosed
US-6099895-A PHOSPHONIC ACID SURFACE MODIFYING COMPOUND IMATION CORP. (US) 2000-08-08 US disclosed
US-5868959-A MAGNETIC PIGMENT HAVING ARALKYL PHOSPHONIC ACID ADSORBED ONTO SURFACE; HIGH SATURATION MAGNETIZATION AND HIGH SURFACE AREA MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014732-A1 Combination of an aldosterone receptor antagonist and an anti-diabetic agent NR3C2, REN, AGTR1 ACP3 1586/4885GRIN2D 3548/4885GRIN3B 2822/4885
US-20230322793-A1 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza MAVS, ZC3HAV1, EIF2AK2 ACP3 4417/4885GRIN2D 4105/4885GRIN3B 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.